Metrics as of 10/17/2026, 02:23 AM (Berlin time), refresh in progress.
Knight Therapeutics Stock
Knight Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- CEO
- Samira Sakhia
- Employees
- 830
- Market cap
- $1.1 B
- IPO
- 03/03/2014
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a…
Knight Therapeutics stock: price history
1D
+2.2%
1W
+1.9%
1M
+10.3%
6M
+44.3%
YTD
+82.5%
1Y
+91.0%
2Y
+95.7%
5Y
+107.1%
10Y
+22.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~51% stronger price swings than usual
Ask the agents about Knight Therapeutics
Analyst assessment of Knight Therapeutics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 06/03/2024
Knight Therapeutics stock metrics
P/E
75.05
P/B
1.36
EV/EBITDA
11.36
RETURN ON EQUITY
-0.4%
NET MARGIN
-2.3%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
61.7%
FLOAT SHARES
60,596,137
AVG. DAILY VOLUME (30D)
84,232
Comparable stocks
Frequently asked questions about Knight Therapeutics stock
What does Knight Therapeutics do?
Knight Therapeutics Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Samira Sakhia, the company employs around 830 people.
The IPO was on 03/03/2014; the stock trades on TSX under the ticker GUD.TO.
What do analysts say about Knight Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 06/03/2024).
This is an external assessment, not a statement by Market Jury.
When does Knight Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does Knight Therapeutics pay a dividend?
No, Knight Therapeutics currently does not pay a dividend.
Which stocks are comparable to Knight Therapeutics?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Knight Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Knight Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.